Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Bone Miner Res ; 19(7): 1059-66, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15176987

RESUMO

UNLABELLED: The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis. INTRODUCTION: RANKL is an essential osteoclastic differentiation and activation factor. MATERIALS AND METHODS: The bone antiresorptive activity and safety of AMG 162, a fully human monoclonal antibody to RANKL, were evaluated in postmenopausal women in this randomized, double-blind, placebo-controlled, single-dose, dose escalation study. Six cohorts of eight to nine women were randomly assigned to receive a single subcutaneous injection of either AMG 162 or placebo (3:1 ratio). AMG 162 doses were 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg. Subjects were followed up to 6 months in all cohorts and 9 months in the three highest dose cohorts. Second morning void urinary N-telopeptide/creatinine (NTX; Osteomark), serum NTX, and serum bone-specific alkaline phosphatase (BALP, Ostase) were assessed as bone turnover markers. RESULTS AND CONCLUSIONS: Forty-nine women were enrolled. A single subcutaneous dose of AMG 162 resulted in a dose-dependent, rapid (within 12 h), profound (up to 84%), and sustained (up to 6 months) decrease in urinary NTX. At 6 months, there was a mean change from baseline of -81% in the 3.0 mg/kg AMG 162 group compared with -10% in the placebo group; serum NTX changes were -56% and 2%, respectively. BALP levels did not decrease remarkably until after 1 month, indicating that the effect of AMG 162 is primarily antiresorptive. Intact parathyroid hormone (PTH) levels increased up to approximately 3-fold after 4 days in the 3.0 mg/kg dose group, but returned toward baseline with follow-up. Albumin-adjusted serum calcium did not decrease >10% on average in any group, and no subject had values below 2 mmol/liter. AMG 162 was well tolerated. No related serious adverse events occurred. No clinically meaningful laboratory changes, other than those described above, were observed. In summary, a single subcutaneous dose of AMG 162 resulted in a dose-dependent rapid and sustained decrease from baseline in bone turnover and could be an effective and convenient treatment for osteoporosis.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Reabsorção Óssea/tratamento farmacológico , Proteínas de Transporte/antagonistas & inibidores , Glicoproteínas de Membrana/antagonistas & inibidores , Idoso , Fosfatase Alcalina/sangue , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/farmacocinética , Anticorpos Monoclonais Humanizados , Reabsorção Óssea/metabolismo , Cálcio/sangue , Proteínas de Transporte/imunologia , Estudos de Coortes , Colágeno/urina , Colágeno Tipo I , Denosumab , Feminino , Humanos , Glicoproteínas de Membrana/imunologia , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Peptídeos/urina , Ligante RANK , Receptor Ativador de Fator Nuclear kappa-B
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA